Brief History of Remedica, a leading pharmaceutical company in the European Union
Remedica's History
2019
2018
2018
-
- Included in the London Stock Exchange List of “1000 Companies to Inspire Europe”
- National winner in the 2018 “European Business Awards”
- Entevirem® (Entecavir) has been approved by the Pharmaceutical Services of the Ministry of Health of Cyprus and more registrations are pending.
- Rezavir® (Darunavir) has received its first regulatory approval by the Pharmaceutical Services Department of the Ministry of Health of Cyprus.
- Trinistem® (Efavirenz 600mg, Emtricitabine 200mg, Tenofovir Disoproxil Succinate 245mg) has received its first regulatory approval.
- Refetib® (Gefetinib, 250mg, Film-Coated Tablets) has received its first regulatory approval.
- Penopen® (Phenoxymethylpenicillin Potassium,1000mg, Film-Coated Tablets), and Penopen® (Phenoxymethylpenicillin Potassium, 800mg, Film-Coated Tablets) have received their first regulatory approval.
2017
2017
-
- Nevalan®, a drug for acid related disorders, Entevirem®, an antiviral for systemic use, Rezavir®, an antiviral for systemic use, and Bradirem®, a cardiac therapy were registered successfully in Cyprus.
- Remedica elected as the best Company in the Ascendis Health Group of Companies
- Co-founded CSR Cyprus
2016
2016
Remedica became part of the Johannesburg-listed healthcare conglomerate Ascendis Health Ltd. As part of this development, Remedica integrated with the Ascendis Health Pharma-Med division and became an important and integral part of a stronger, international player.
2015
2015
- Remedica won a place in the final top 10 best export companies across Europe (Ruban d’Honneur) at the European Business Awards.
- The company was successfully inspected by the Iranian Authorities (IFDA)